Researchers at Oxford University said on Thursday that the risk of developing rare blood clots is higher after COVID-19 infection than for people who have been vaccinated.
The findings come a new study published by the university, which contributed to the development of the AstraZeneca vaccine, which has now come under control for potential links to a blood clot known as cerebral venous sinus thrombosis (CVST).
After comparing the number of CVST cases in the two weeks after the diagnosis of COVID-19 and the first dose of vaccine, Oxford reports that the risk of developing blood clots is up to 10 times higher due to a COVID-19 infection than is after a vaccination.
The researchers noted that, compared to Pfizer and Moderna vaccines, the risk of developing CVST is about 10 times higher, while the risk is about eight times higher compared to Oxford-AstraZeneca inoculation.
While the study noted that data on potential links between vaccines and blood clots are still under review, Paul Harrison, head of the Oxford Translational Neurobiology Group, said Thursday’s findings “should be taken into account when considering take into account the balances between the risks and benefits of vaccination. . ”
The study comes after a wave of countries limited the use of the AstraZeneca vaccine to older age groups due to reports of blood clots.
On Wednesday, Denmark became the first European country to stop completely use of AstraZeneca photography after an investigation “It showed real and serious side effects,” according to the Danish Health Authority.
A Safety Committee of the European Medicines Agency (EMA) he said last week that there is a “possible link” between the AstraZeneca vaccine and blood clots, although he added that the benefits of inoculation to protect against COVID-19 outweigh the risks.
The Oxford study did not include data on the Johnson & Johnson shooting, which was discontinued in the United States on the recommendation of health authorities analyzing six cases of blood clots among the 7 million people who received the shot.
An independent advisory group from the Centers for Disease Control and Prevention on Wednesday postponed a recommendation on the Johnson & Johnson shot until there was more evidence of blood clots, likely extending the distribution of one of three federally approved coronavirus vaccines for use. emergency in the US